Pasar al contenido principal

ABORDAJE MECANISTICO DE LA REPROGRAMACION METABOLICA DIFERENCIAL ENTRE TUMORES Y CELULAS INMUNES PARA EL TRATAMIENTO DE LA INMUNORRESISTENCIA ADQUIRIDA EN CANCER

PID2019-107139RB-C21

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A novel gene signature unveils three distinct immune-metabolic rewiring patterns conserved across diverse tumor types and associated with outcomes

  • Pedrosa, Leire
  • Foguet, Carles
  • Oliveres, Helena
  • Archilla, Iván
  • García de Herreros, Marta
  • Rodríguez, Adela
  • Postigo, Antonio
  • Benítez-Ribas, Daniel
  • Camps, Jordi
  • Cuatrecasas, Miriam
  • Castells, Antoni
  • Prat, Aleix
  • Thomson, Timothy M.
  • Maurel, Joan
  • Cascante, Marta
Existing immune signatures and tumor mutational burden have only modest predictive capacity for the efficacy of immune check point inhibitors. In this study, we developed an immune-metabolic signature suitable for personalized ICI therapies. A classifier using an immune-metabolic signature (IMMETCOLS) was developed on a training set of 77 metastatic colorectal cancer (mCRC) samples and validated on 4,200 tumors from the TCGA database belonging to 11 types. Here, we reveal that the IMMETCOLS signature classifies tumors into three distinct immune-metabolic clusters. Cluster 1 displays markers of enhanced glycolisis, hexosamine byosinthesis and epithelial-to-mesenchymal transition. On multivariate analysis, cluster 1 tumors were enriched in pro-immune signature but not in immunophenoscore and were associated with the poorest median survival. Its predicted tumor metabolic features suggest an acidic-lactate-rich tumor microenvironment (TME) geared to an immunosuppressive setting, enriched in fibroblasts. Cluster 2 displays features of gluconeogenesis ability, which is needed for glucose-independent survival and preferential use of alternative carbon sources, including glutamine and lipid uptake/β-oxidation. Its metabolic features suggest a hypoxic and hypoglycemic TME, associated with poor tumor-associated antigen presentation. Finally, cluster 3 is highly glycolytic but also has a solid mitochondrial function, with concomitant upregulation of glutamine and essential amino acid transporters and the pentose phosphate pathway leading to glucose exhaustion in the TME and immunosuppression. Together, these findings suggest that the IMMETCOLS signature provides a classifier of tumors from diverse origins, yielding three clusters with distinct immune-metabolic profiles, representing a new predictive tool for patient selection for specific immune-metabolic therapeutic approaches., This study was supported by grants from the Spanish Ministry of Science and Innovation (MICINN) SAF2017-84918-R0 (National Scientific and Technical Research and Innovation 2017–2020 Plan, co-funded by the EUC-ERDF) to APr, PID2019-107139RB-C21 to TT, and PID2020-115051RB-I00 to MCa funded by MCIN/AEI/10.13039/501100011033; grants from Fundació la Marató de TV3 (201330.10) to APo, Foundation Olga Torres (Biannual Grant A-2019/2020) to APo, and Fundació ICREA-Premi Icrea Academia to MCa; grants from Catalan Agency for Management of University and Research Grants (AGAUR) 2017-SGR-1174 to APo and 2017-SGR-1033 to MCa and Spanish Association Against Cancer (AECC, PROYE19040POST_001) to APo and JM; and grants from Instituto de Salud Carlos III (PI13/01728 and PI19/0740) to JM.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Autochthonous Peruvian Natural Plants as Potential SARS-CoV-2 Mpro Main Protease Inhibitors

  • Peralta-Moreno, María Nuria
  • Antón-Muñoz, Vanessa
  • Ortega-Alarcón, David
  • Jiménez-Alesanco, Ana
  • Vega, Sonia
  • Abian, Olga
  • Velázquez-Campoy, Adrián
  • Thomson, Timothy M.
  • Granadino-Roldán, José Manuel
  • Machicado, Claudia
  • Rubio-Martínez, Jaime
Over 750 million cases of COVID-19, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), have been reported since the onset of the global outbreak. The need for effective treatments has spurred intensive research for therapeutic agents based on pharmaceutical repositioning or natural products. In light of prior studies asserting the bioactivity of natural compounds of the autochthonous Peruvian flora, the present study focuses on the identification SARS-CoV-2 Mpro main protease dimer inhibitors. To this end, a target-based virtual screening was performed over a representative set of Peruvian flora-derived natural compounds. The best poses obtained from the ensemble molecular docking process were selected. These structures were subjected to extensive molecular dynamics steps for the computation of binding free energies along the trajectory and evaluation of the stability of the complexes. The compounds exhibiting the best free energy behaviors were selected for in vitro testing, confirming the inhibitory activity of Hyperoside against Mpro, with a Ki value lower than 20 µM, presumably through allosteric modulation., This research was funded by The Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR)-Generalitat de Catalunya (2021SGR00350) and Spanish Structures and Excellence María de Maeztu program, grant number CEX2021-001202-M. Universitat de Barcelona PREDOCS-UB 2020 grant (5760700—Institut de Química Teòrica i Computacional to M.N.P.-M.), Fundación hna (to A.V.C. and O.A.), Fondo Investiga COVID-19 from Instituto de Investigación Sanitaria de Aragón IIS-A (to O.A. and A.V.-C.), Spanish Ministry of Economy and Competitiveness (BFU2016-78232-P to A.V.C., FPI predoctoral contract BES-2017-080739 to D.O.A.), Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033/and “ERDF A way of Making Europe” (PID2021-127296OB-I00 to A.V.C.), Fondo de Investigaciones Sanitarias from Instituto de Salud Carlos III and European Union (ERDF/ESF, “Investing in your future”) (PI18/00349 and PI21/00394 to O.A.), Diputación General de Aragón (Protein Targets and Bioactive Compounds Group E45_20R to A.V.C., Digestive Pathology Group B25_20R to O.A., and predoctoral contract 2019 to A.J.A.). Consejo Superior de Investigaciones Científicas (COV-006 and COV-201 to T.M.T.), Plataforma Temática Interdisciplinar Salud Global (PTI-SG + SGL2103019 to T.M.T.). Agència de Gestió d’Ajuts Universitaris i de Recerca (2020PANDE00048 to J.R.M and T.M.T.). Plan Nacional de I + D (PID-107139RB-C21 to T.M.T.)., With funding from the Spanish government through the ‘María de Maeztu Unit of Excelence’ accreditation (CEX2021-001202-M), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

On the importance for drug discovery of a transnational Latin American database of natural compound structures

  • Thomson, Timothy M.
Drug development is a complex, risky, expensive and time-consuming process that requires the accurate execution of multiple stages, from identification and selection of collections of potentially druggable molecules to proof-of-concept validation. Prior to embarking on a drug discovery project, a detailed strategic plan must be designed that includes hundreds of critical considerations such as source of compounds for screening, feasibility of their synthetic pathways, target selection (molecules, cells, organisms), type of output (binding, function, phenotype), throughput, nature, layers and iterations of the screening process, scoring systems, lead optimization approaches or model systems for validation (biochemical activity, cellular function, organismal properties) and, crucially, good contingency plans. The need to discover new drugs rests on practical matters of human progress, rather than mere market considerations. For example, the global emergence of multidrug resistant pathogens makes it a research target to find alternative antibiotics; current cancer drugs, including advanced biologicals, face drug resistance; many parasitic diseases lack effective drug treatments; highly prevalent neurodegenerative diseases and rare diseases, which collectively affect significant numbers of people, are essentially drug orphan; vital agricultural crops are plagued by fungal and parasitic diseases that have evolved to become increasingly resistant to currently available chemicals. The current COVID-19 pandemic illustrates how pharmaceutically unprepared humanity is (vaccines aside) to confront the sudden emergence of a novel, deadly and highly transmissible pathogen. To date, only a handful of repurposed drugs display demonstrable therapeutic efficacy against infection and disease by the causing agent, SARS-CoV-2 (Lui and Guaraldi, 2023; Sandulescu et al., 2023). Despite an unprecedented parallel effort by hundreds of thousands of industrial and academic scientists worldwide, employing leading-edge technologies, no new drugs have been discovered over the past 3 years to effectively treat this disease., The author’s work is supported by the Spanish Ministry of Science and Technology (PID 2019-107139RB-C21), the Interdisciplinary Platform-Global Health (Plataforma Temática Interdisciplinar-Salud Global, PTI-SG) (SGL2103019) and the Networked Researched Center on Liver and Digestive Diseases (Centro de Investigación en Red en Enfermedades Hepáticas y Digestivas, CIBER-EHD)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Autonomous metabolic reprogramming and oxidative stress characterize endothelial dysfunction in acute myocardial infarction

  • Zodda, Erika
  • Tura-Ceide, Olga
  • Mills, Nicholas L.
  • Tarragó‐Celada, Josep
  • Carini, Marina
  • Thomson, Timothy M.
  • Cascante, Marta
Compelling evidence has accumulated on the role of oxidative stress on the endothelial cell (EC) dysfunction in acute coronary syndrome. Unveiling the underlying metabolic determinants has been hampered by the scarcity of appropriate cell models to address cell-autonomous mechanisms of EC dysfunction. We have generated endothelial cells derived from thrombectomy specimens from patients affected with acute myocardial infarction (AMI) and conducted phenotypical and metabolic characterizations. AMI-derived endothelial cells (AMIECs) display impaired growth, migration, and tubulogenesis. Metabolically, AMIECs displayed augmented ROS and glutathione intracellular content, with a diminished glucose consumption coupled to high lactate production. In AMIECs, while PFKFB3 protein levels of were downregulated, PFKFB4 levels were upregulated, suggesting a shunting of glycolysis towards the pentose phosphate pathway, supported by upregulation of G6PD. Furthermore, the glutaminolytic enzyme GLS was upregulated in AMIECs, providing an explanation for the increase in glutathione content. Finally, AMIECs displayed a significantly higher mitochondrial membrane potential than control ECs, which, together with high ROS levels, suggests a coupled mitochondrial activity. We suggest that high mitochondrial proton coupling underlies the high production of ROS, balanced by PPP- and glutaminolysis-driven synthesis of glutathione, as a primary, cell-autonomous abnormality driving EC dysfunction in AMI., The project leading to this work has received funding from: The European Commission Horizon 2020 research and innovation program under the MOGLYNET H2020-MSCA-ITN-EJD grant (agreement No 675527); CIBER- Carlos III National Institute of Health, Spain (TT and MCas: CIBEREHD-CB17/04/00023; OTC: CIBERES-CP17/00114); Spanish Ministerio de Economia y Competitividad (MINECO) and Ministerio de Ciencia e Innovación -European Commission FEDER funds—'Una manera de hacer Europa' (TT: PID2019-107139RB-C21 and MCas: PID2020-115051RB-I00); Generalitat de Catalunya-AGAUR (MCas: ICREA Academia Prize 2021, MCas: 2021 SGR00350; TT: 2021 SGR1490); Plataforma Temática Interdisciplinary – Salud Global (TT: SGL2103019); NLM is supported by the British Heart Foundation (RE/18/5/34216, RG/20/10/34966, CH/F/21/90010)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Shedding Light on Dark Chemical Matter: The Discovery of a SARS-CoV-2 Mpro Main Protease Inhibitor through Intensive Virtual Screening and In Vitro Evaluation

  • Peralta-Moreno, María Nuria
  • Mena, Yago
  • Ortega-Alarcón, David
  • Jiménez-Alesanco, Ana
  • Vega, Sonia
  • Abian, Olga
  • Velázquez-Campoy, Adrián
  • Thomson, Timothy M.
  • Pinto, Marta
  • Granadino-Roldán, José Manuel
  • Santos Tomás, María
  • Pérez, Juan J.
  • Rubio-Martínez, Jaime
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., The development of specific antiviral therapies targeting SARS-CoV-2 remains fundamental because of the continued high incidence of COVID-19 and limited accessibility to antivirals in some countries. In this context, dark chemical matter (DCM), a set of drug-like compounds with outstanding selectivity profiles that have never shown bioactivity despite being extensively assayed, appears to be an excellent starting point for drug development. Accordingly, in this study, we performed a high-throughput screening to identify inhibitors of the SARS-CoV-2 main protease (Mpro) using DCM compounds as ligands. Multiple receptors and two different docking scoring functions were employed to identify the best molecular docking poses. The selected structures were subjected to extensive conventional and Gaussian accelerated molecular dynamics. From the results, four compounds with the best molecular behavior and binding energy were selected for experimental testing, one of which presented inhibitory activity with a Ki value of 48 ± 5 μM. Through virtual screening, we identified a significant starting point for drug development, shedding new light on DCM compounds., This research was funded by The Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR)-Generalitat de Catalunya (2021SGR00350) and the Spanish Structures and Excellence María de Maeztu program, grant number CEX2021-001202-M; the Universitat de Barcelona PREDOCS-UB 2020 grant (5760700—Institut de Química Teòrica i Computacional to M.N.P.-M.); Fundación hna (to A.V.C. and O.A.); Fondo Investiga COVID-19 from Instituto de Investigación Sanitaria de Aragón IIS-A (to O.A. and A.V.-C.); the Spanish Ministry of Economy and Competitiveness (BFU2016-78232-P to A.V.C., FPI predoctoral contract BES-2017-080739 to D.O.A.); the Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033/ and “ERDF A way of Making Europe” (PID2021-127296OB-I00 to A.V.C.); the Fondo de Investigaciones Sanitarias from Instituto de Salud Carlos III and European Union (ERDF/ESF, “Investing in your future”) (PI18/00349 and PI21/00394 to O.A.); the Diputación General de Aragón (Protein Targets and Bioactive Compounds Group E45_23R to A.V.C., Digestive Pathology Group B25_23R to O.A., and predoctoral contract 2019 to A.J.A.); the Consejo Superior de Investigaciones Científicas (COV-006 and COV-201 to T.M.T.); the Plataforma Temática Interdisciplinar Salud Global (PTI-SG + SGL2103019 to T.M.T.); the Agència de Gestió d’Ajuts Universitaris i de Recerca (2020PANDE00048 to J.R.-M and T.M.T.); and the Plan Nacional de I + D (PID-107139RB-C21 to T.M.T.)., With funding from the Spanish government through the ‘María de Maeztu Unit of Excelence’ accreditation (CEX2021-001202-M)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells

  • Tarrado‐Castellarnau, Míriam
  • Foguet, Carles
  • Tarragó‐Celada, Josep
  • Palobart, Marc
  • Hernández-Carro, Claudia
  • Perarnau, Jordi
  • Zodda, Erika
  • Polat, Ibrahim H.
  • Marín, Silvia
  • Suarez-Bonnet, Alejandro
  • Lozano, Juan José
  • Yuneva, Mariia
  • Thomson, Timothy M.
  • Cascante, Marta
Several mechanisms of resistance of cancer cells to cyclin-dependent kinase inhibitors (CDKi) have been identified, including the upregulation of metabolic regulators such as glutaminase. However, whether such resistance mechanisms represent optimal targets has not been determined. Here, we have systematically analyzed metabolic reprogramming in colorectal cancer cells exposed to Palbociclib, a CDKi selectively targeting CDK4/6, or Telaglenastat, a selective glutaminase inhibitor. Through multiple approaches, we show that Palbociclib and Telaglenastat elicit complementary metabolic responses and are thus uniquely suited to counter the metabolic reprogramming induced by the reciprocal drug. As such, while Palbociclib induced reduced tumor growth in vivo, and Telaglenastat did not show a significant effect, the drug combination displayed a strong synergistic effect on tumor growth. Likewise, initial responses to Palbociclib were followed by signs of adaptation and resistance, which were prevented by combining Palbociclib with Telaglenastat. In conclusion, combination with Telaglenastat optimally forestalls acquired resistance to Palbociclib in cancer cells., This work was supported by I + D + i projects PID2023-150539OB-I00, PID2020-115051RB-I00, and PID2019-107139RB-C21, funded by MICIU/AEI/10.13039/501100011033/ European Commission FEDER funds “Una manera de hacer Europa”, the Interdisciplinary Platform-Global Health (Plataforma Temática Interdisciplinar-Salud Global, PTI-SG; SGL2103019), the Networked Researched Center on Liver and Digestive Diseases (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas, CIBER-EHD; EHD20PI03 and CB17/04/00023), the Catalan Agency for Universities and Research (AGAUR) (2021-SGR-00350 and 2021-SGR-01490), ICREA Foundation (ICREA Academia award granted to M. Cascante) and The Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001223), the UK Medical Research Council (FC001223) and the Wellcome Trust (FC001223)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Autochthonous Peruvian natural plants as potential SARS-CoV-2 Mpro main protease inhibitors

  • Peralta-Moreno, M. N.
  • Antón-Muñoz, V.
  • Ortega-Alarcón, D.
  • Jiménez-Alesanco, A.
  • Vega, S.
  • Abian, O.
  • Velázquez-Campoy, A.
  • Thomson, T. M.
  • Granadino-Roldán, J. M.
  • Machicado, C.
  • Rubio-Martínez, J.
Over 750 million cases of COVID-19, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), have been reported since the onset of the global outbreak. The need for effective treatments has spurred intensive research for therapeutic agents based on pharmaceutical repositioning or natural products. In light of prior studies asserting the bioactivity of natural compounds of the autochthonous Peruvian flora, the present study focuses on the identification SARS-CoV-2 Mpro main protease dimer inhibitors. To this end, a target-based virtual screening was performed over a representative set of Peruvian flora-derived natural compounds. The best poses obtained from the ensemble molecular docking process were selected. These structures were subjected to extensive molecular dynamics steps for the computation of binding free energies along the trajectory and evaluation of the stability of the complexes. The compounds exhibiting the best free energy behaviors were selected for in vitro testing, confirming the inhibitory activity of Hyperoside against Mpro, with a Ki value lower than 20 µM, presumably through allosteric modulation.